What is the future of PEGylated therapies?

Magdalena Swierczewska, Kang Choon Lee, Seulki Lee

Research output: Contribution to journalReview articlepeer-review

105 Scopus citations


The tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies. PEGylation is the first successful technology to improve pharmacokinetic (PK) profiles of therapeutic agents and has been applied in the clinic for over 25 years. Over 10 PEGylated therapeutics have entered the clinic since the early 1990s, and new PEGylated agents continue to expand clinical pipelines and drug patent life. PEGylation is the most established half-life extension technology in the clinic with proven safety in humans for over two decades. Still, it is one of the most evolving and emerging technologies that will be applied for the next two decades.

Original languageEnglish (US)
Pages (from-to)531-536
Number of pages6
JournalExpert Opinion on Emerging Drugs
Issue number4
StatePublished - Oct 2 2015


  • PEGylation
  • half-life extension
  • peptide delivery
  • protein delivery

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'What is the future of PEGylated therapies?'. Together they form a unique fingerprint.

Cite this